However, the young age, lack of breed diversity and small number of study animals preclude drawing any conclusions regarding a similar outcome for adult horses. Therefore, the purpose of our study was to describe the clinical and clinicopathological findings in adult horses experimentally infected with ECoV. We hypothesized that by means of gut-derived ECoV, a reproducible animal model of infection would mimic clinical signs of natural disease. Our study differs from the previous report in that a larger number of demographically relevant adult horses were used. Additionally, our study sought to establish a fecaloral route of infection as a model for future studies.
| MATERIALS AND METHODS

| Animals
Eight clinically healthy, lightbreed, adult horses, aged 6-15 years, and ranging in weight from 500 to 625 kg, composed of 3 geldings and 5 mares were included in the study. The "light" breeds consisted of Thoroughbreds (3), Warmbloods (2), Oldenburg (1), Holsteiner (1), Quarter Horse (1), and 1 each of Thoroughbred/Quarter Horse cross, and Warmblood/Quarter Horse cross. Before study commencement, all 8 horses were screened for current illness by CBC and physical examination including temperature, heart rate, respiratory rate, thoracic and abdominal auscultation, assessment of mentation, mucous membrane quality and color, and evaluation of fecal consistency. All physical examinations and CBCs were within normal limits. In addition, before the study started, all study horses tested seronegative for ECoV-specific antibodies using a recently established enzyme-linked immunosorbent assay (ELISA). 10 Furthermore, fecal samples from all horses were collected and tested for ECoV, Clostridium difficile toxins A and B, Clostridium perfringens, Neorickettsia risticii, rotavirus, Lawsonia intracellularis using qPCR and Salmonella spp. using microbiological culture. All horses were negative for all screened pathogens. Fecal egg counts to determine parasite burden were not performed. The horses were randomly assigned to either the experimentally-infected group (group 1) or the naturally-exposed group (group 2) for this randomized experimental study. All procedures were approved by the Institutional Animal Care and Use Committee of the University of California.
| Study design
An isolation unit, including anterooms, foot baths, and solid walls to prevent horse-to-horse contact, provided housing for the horses throughout the course of the randomized, experimental study. One day before initiation of the study, the horses were moved to the isolation unit and allowed to accommodate to their new environment, where they remained for the duration of the study (15 days). The horses were fed equal parts grass hay and alfalfa hay twice daily at a total of 1.5% body weight and supplemented with a small amount of commercial sweet feed product twice daily. Horses were allowed free access to water. Stalls were cleaned twice daily.
| Intragastric inoculation and exposure
The ECoV inoculum used in the experimental infection group originated from the small intestinal content of an American Miniature Horse. This horse died from endotoxemic shock secondary to ECoV infection confirmed at necropsy. 2 The intestinal contents of that horse were tested and found to be negative for Salmonella enterica, C. difficile toxins A and B, N. risticii, and L. intracellularis by culture or qPCR and subsequently stored at −80 C. Electron microscopy confirmed that this sample contained ECoV-like viral particles, which were quantified by qPCR as previously described 8 
| Monitoring and sample collection
Physical examination and observation of attitude, appetite, and fecal quality were performed twice daily on all horses. Once daily, feces from the stall floor, nasal swab, and whole blood samples were collected for quantitative molecular detection of ECoV. Whole blood (ethylenediaminetetraacetic acid [EDTA]) was collected for CBC every other day. Before study commencement and once weekly thereafter (up to 28 days post infection), additional blood was collected for serological analysis, using a recently validated ELISA. 10 Clinical disease was defined as presence of at least 1 of the following signs: lethargy, anorexia (partial or complete), alteration of fecal consistency, rectal temperature >101.5 F, and signs of colic, such as pawing, flank watching, or repeated rolling. Alteration of fecal consistency was defined as soft, formed (increased water content such that the feces easily changed shape upon contact with the ground but maintained at least partially the form of fecal balls), loose (increased water content such that feces flattened upon contact with the ground without any form), or liquid (increased water content such that manure would take the shape of any container in which it was placed).
| Sample analysis
Nucleic acid extraction from EDTA whole blood, nasal secretions (collected with a 6-inch, rayon-tipped swab), and feces was performed the day of sample collection by an automated nucleic acid extraction system (CAS-1820 X-tractor Gene, Corbett Life Science, Sydney, Australia) according to the manufacturer's recommendations. The purified RNA then was analyzed by qPCR for presence and quantitation of the N gene of ECoV. 11 A specific 142-basepair sequence of the N gene was used to distinguish ECoV particles and a bacterial 16S rRNA gene was used as quality control and a marker of fecal inhibition.
Amplification efficiency was calculated from the slope of a standard curve that was run for the assay, using the formula E = 10 1/−s − 3 | RESULTS
| Physical examination
The clinical findings are summarized in Table 1 
| Test results
Laboratory results are summarized in Table 1 . Complete blood count indicated total nucleated cell count within the normal ranges for all horses throughout the study. Additionally, mild lymphopenia (reference range, 1600-5800 cells/μL) was noted in 2 horses of group 1 at 4 DPI (Table 1 and Figure 1 ) and in 2 horses of group 2 ( Table 1 and Figure 2 ). Plasma fibrinogen concentration was evaluated by the heat precipitation method and remained within normal limits in all horses throughout the study. (Table 1) for 2, usually nonconsecutive, days. In group 1 horses, nasal shedding occurred 2 days after onset of fecal shedding. In group 2 horses, nasal shedding occurred 3-5 days after exposure, and 3 days before onset of fecal shedding. Only Horse 4 exhibited detectable viremia at 12 DPI (Table 1) . 
| PCR analysis
| Serology
| DISCUSSION
We were successful in establishing ECoV infection in adult horses.
Although the clinical signs were variable and short-lived, all horses consistently shed ECoV in their feces. Furthermore, our study supports a fecal-oral route of infection for ECoV. The clinical signs (changes in fecal character and fever) varied in frequency and intensity between the 2 infected groups and among individuals within the same group. However, a consistent finding was the presence of abnormal manure in all of the group 1 horses between 2 and 4 DPI. Fever was an inconsistent finding and not noted in any of the group 2 horses.
Two horses from each group experienced a mild, transient lymphopenia. Interestingly, the inoculated horses (group 1) tended to experience this change slightly later, at 4-5 DPI, whereas the naturallyexposed horses (group 2) that became lymphopenic, did so at 3 DPI.
Although all of the infected horses became fecal qPCR-positive for ECoV in both our study and a previous study, 9 our results show that horses can shed virus intermittently. In fact, Horse 1 shed virus in feces from 4 to 7 DPI, shed no virus for 8-11 DPI, then again shed virus for a single day 12 DPI. This finding indicates the importance of repeated testing before reintroducing horses to the herd. Additionally, no statistically significant difference was found in fecal viral shedding among horses that were primarily inoculated and those that were exposed naturally. Therefore, asymptomatic horses in the herd can shed virus that can infect healthy horses if fecal material is allowed to contaminate feed or water.
In our study, some of the positive nasal results occurred the day after peak fecal shedding. This correlation is suggestive of spread cannot be ruled out in our study.
Clinical signs noted in our study were mild. We believe this finding is representative of many of the clinical cases seen in practice.
Fever combined with loss of appetite, with or without changes in manure quality, is seen frequently in horses that test qPCR positive for ECoV only in feces and go on to fully recover with supportive care.
However, the infected horses can manifest a wide spectrum of clinical signs from mild colic with fever to severe enterocolitis with sepsis that can be lethal in some cases. 5 The reason for this difference is as yet unknown and may be dose related. In our study, the largest horse (Horse 4) was the most severely affected (Table 1) , and therefore dose dependency warrants further investigation.
Because experimental infection with ECoV is relatively novel, comparison to epidemiological studies is necessary. can be the case with cultured virus. The virus source used in our study was feces of a previously infected horse as opposed to pure viral culture, because of difficulty in performing the latter, 12 and in agreement with a previous study. 9 Electron microscopy could have been used instead of virus isolation. However, given the low sensitivity of the former test 13 and previous documentation of the use of qPCR for the highly conserved N protein, 4, 14 we are confident in the performance of the qPCR used for the detection of ECoV. Therefore, other diagnostic modalities were not pursued in the study horses.
The power of our study is limited by the small sample size of horses. Overall, however, we believe our study describes an accurate model for ECoV, inducing clinical and laboratory abnormalities similar to those of natural mild infection. Additional studies are warranted to determine the differences between mild and severe cases, including inoculation doses, environmental factors, and comorbidities.
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